Lexaria Bioscience Corp updates on progress of its DehydraTECH CBD research to deal with hypertension

In the human study HYPER-H21-1, the recruitment of 24 volunteers with otherwise untreated pre- or mild hypertension has begun, and dosing of a single dose of 300 mg of CBD with or without enhancement of the DehydraTECH formulation is expected to be completed by May this year

Lexaria Bioscience Corp (CSE: LXX) (OTCMKTS: LXRP) has announced progress to investors in evaluating its DehydraTECH CBD technology in the treatment of high blood pressure, and noted that all five studies scheduled for this year are currently ongoing.

Three human clinical studies and two animal studies are currently ongoing.

READ: Lexaria Bioscience Expands DehydraTECH’s CBD Hypertension Program with Two New Human Studies. Updates for others

In the human study HYPER-H21-1, the recruitment of 24 volunteers with otherwise untreated pre- or mild hypertension has begun, and dosing of a single dose of 300 mg of CBD with or without enhancement of the DehydraTECH formulation is expected to be completed by May this year.

In the human study HYPER-H21-2, formal applications from hospitals and ethics committees have been approved for an upcoming European study, and the test items are expected to arrive at the research site as early as next week. After that, recruitment of 16 volunteers will begin soon, Lexaria said.

The third study also received formal approvals from hospitals and ethics committees for a European human clinical trial. The test items are expected to arrive at the research site as early as next week. 16 volunteers will then be recruited once recruitment for the HYPER-H21-1 and HYPER-H21-2 studies is complete.

In the animal studies, in the HYPER-A21-1 study, the results should be reported in or around the first half of May this year. Dosing is complete and no observed behavior tolerance problems have been observed during or after treatment. This study evaluates the rate of absorption and the rate at which various new improved DehydraTECH experimental trial formulations – “DehydraTECH 2.0” – deliver CBD to the bloodstream and brain.

In the second HYPER-A21-2 study, dosing is scheduled to begin next week and in this animal study is expected to be completed by March 30th. This study will also evaluate the rate of absorption and speed at which additional DehydraTECH 2.0-enhanced formulations of CBD are administered into the bloodstream and brain. The results should be released in or around the first half of June, Lexaria said.

Lexaria is a Canadian company with a patented technology that promises to change the way drugs are delivered into the body. These research and development studies are an important early step in building business relationships with potential industrial partners to use DehydraTECH in existing product lines or to develop new ones.

The annual US market for high blood pressure drugs is $ 28 billion. The direct health care costs of patients with pulmonary arterial hypertension have been estimated at $ 29,712 to $ 142,500 per year.

Lexaria holds 18 issued patents internationally, including emissions in the European Union and Australia specifically used for the use of DehydraTECH-processed CBD to treat heart disease.

Contact the author at [email protected]